initiated with intravenous meropenem (3g/day), tigecycline (100 mg every 12 h) and clindamycin (600 mg/day). Filgastrim (48000 μg/day subcutaneous) was also administered.

Mucormycosis: an emerging disease?REVIEW Mucormycosis: an emerging disease? E. Bouza, P. Munoz and J. Guinea Servicio de Microbiologa Clnica y Enfermedades Infecciosas, Hospital

Ivett Miranda1 Jorge Ocampo-Candiani1 Oliverio Welsh1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20176614 Abstract: Cutaneous mucormycosis is an emerging fungal infection

J Clin Exp Dent. 2011;3(3):e256-60. Rhino Cerebral Mucormycosis. Journal section: Oral Medicine and Pathology doi:10.4317/jced.2.e256 Publication Types: Case Report Rhino

Current Trends in Pharmaceutical Research, 2021 Vol 8 Issue 1 © Dibrugarh University www.dibru.ac.in/ctpr ISSN: 2319-4820 (Print) 2582-4783 (Online) *Corresponding author’s

Mucormycosis in Australia: contemporary epidemiology and outcomesContents lists avai Original article Mucormycosis in Australia: contemporary epidemiology and outcomes K.J.

Ivett Miranda1 Jorge Ocampo-Candiani1 Oliverio Welsh1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20176614 Abstract: Cutaneous mucormycosis is an emerging fungal infection

ECMM/ISHAM recommendations for clinical management of COVID 19 associated mucormycosis in low and middleincome countriesSubmitted on 8 Sep 2021 HAL is a multi-disciplinary

Correspondence: Ugur Onal, Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bornova Izmir Turkey Email: [email protected]